Recently, immune checkpoint inhibitors (ICIs), including ipilimumab (the CTLA-4 inhibitor) and nivolumab (the PD-1 inhibitor), have demonstrated great survival benefits in patients with HCC (Waidmann, 2018; Lee et al., 2019). Here, CTLA4 is linked to hepatocellular carcinoma.